Clinical Evidence: What the Trial Data Tell Pharmacists

In this episode, Ali breaks down the pivotal trial data for revumenib and ziftomenib, comparing response rates, transplant outcomes, and patient populations studied. He reveals which efficacy numbers pharmacists should know before their first order review and explains why transplant rate is as clinically meaningful as overall response rate when evaluating therapy success.